What is Kintor Pharmaceutical Operating Cash Flow per Share?
Kintor Pharmaceutical's operating cash flow per share for the
six
months ended in Dec. 2023 was HK$-0.44.
Kintor Pharmaceutical's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.99.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 12.20% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -34.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Kintor Pharmaceutical's Operating Cash Flow per Share or its related term are showing as below:
HKSE:09939'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -117.1 Med: -60.7 Max: 12.2
Current: 12.2
During the past 6 years, Kintor Pharmaceutical's highest 3-Year average Operating Cash Flow per Share Growth Rate was 12.20% per year. The lowest was -117.10% per year. And the median was -60.70% per year.
HKSE:09939's 3-Year OCF Growth Rate is ranked better than 58.46% of 1235
companies
in the Biotechnology industry
Industry Median: 3.3
vs HKSE:09939: 12.20
Kintor Pharmaceutical Operating Cash Flow per Share Historical Data
The historical data trend for Kintor Pharmaceutical's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Kintor Pharmaceutical Operating Cash Flow per Share Chart
Competitive Comparison of Kintor Pharmaceutical's Operating Cash Flow per Share
For the Biotechnology subindustry, Kintor Pharmaceutical's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's Price-to-Operating-Cash-Flow falls into.
Kintor Pharmaceutical Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Kintor Pharmaceutical's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.99
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Kintor Pharmaceutical's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Kintor Pharmaceutical (HKSE:09939) Business Description
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09939 has been successfully added to your 